Navigation Links
JDRF and BD Collaborate to Improve Insulin Pump Delivery

R&D Program Targets Opportunities to Improve Glucose Control and Help People with Diabetes Lead Healthier Lives

NEW YORK and FRANKLIN LAKES, N.J., Jan. 19 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.  

Through the program, JDRF will support BD's research and development of new products that deliver insulin from a pump to a patient in either an infusion set or patch-pump configuration.  Research indicates that there are significant opportunities to enhance pump therapy by improving convenience as well as minimizing pain, kinking, occlusions and site infections.  An additional goal of the program is improving the speed at which insulin works.  These enhancements are intended to improve how people with diabetes control their insulin therapy and have a positive impact on their overall level of glycemic control.

"Better control means better health outcomes for people with diabetes," said Alan Lewis, Ph.D., President and Chief Executive Officer of JDRF.  "Constantly improving the technological tools to dispense insulin will lead to greater adoption of these methods and healthier lives.  That's why we view this collaboration with BD as vital to our goal to provide a bridge to the cure for type 1 diabetes."  

The JDRF will invest $4.3 million in milestone-based financial support over the next few years for these projects.

"Providing reliable, convenient and cost-effective insulin delivery options is vital to helping people manage diabetes," said Linda Tharby, President, BD Medical - Diabetes Care.  "This collaboration with JDRF demonstrates BD's commitment to leveraging our expertise as a leader in insulin injection and acute care infusion to improve the patient experience for insulin pump users."

The evaluation of new delivery technologies, including BD microneedles, will be an important objective of this program.  Microneedles are tiny needles that deliver insulin just beneath the skin, increasing the speed of insulin uptake and may be virtually pain free.  Microdelivery technology development will focus on improved glucose control and ultimately the use of the technology as a critical element of closed-loop artificial pancreas systems.  One day these systems might sense blood glucose levels and automatically administer the proper dosage of insulin in response.

Type 1 diabetes is an autoimmune disease in which the immune system attacks and kills off the cells in the pancreas that produce insulin, a hormone that enables people to convert food into energy.  It affects children, adolescents and adults.

To manage this disease, people with type 1 diabetes need to measure their blood sugar and pump or inject insulin throughout the day to keep blood sugar levels within a healthy range.  This daily routine continues for life because insulin does not cure diabetes.  

According to JDRF's estimates, approximately 400,000 of the 3 million people in the United States with type 1 diabetes use insulin pumps, which became commercially available in the 1980s.  Pumps offer flexibility and precision in controlling diabetes, which is a constant challenge for someone with diabetes.  In fact, research shows that most people with diabetes spend the majority of the day with blood sugar levels outside recommended ranges, which can lead to devastating and costly short- and long-term complications.

About JDRF's Artificial Pancreas Project

The JDRF/BD research program is among the first major non-exclusive industry initiatives of the JDRF Artificial Pancreas Project.  JDRF last week announced that it is partnering with Animas Corporation, a Johnson & Johnson company, in a non-exclusive four-year program to develop a first-generation artificial pancreas system.  The eventual, ultimate goal of the JDRF Artificial Pancreas Project is speeding the development of fully automated diabetes management systems.  

An artificial pancreas would measure blood sugar through a continuous glucose monitor (CGM) which continuously reads the glucose levels through a hair-thin tube inserted just below the skin, typically on the stomach.  The CGM would beam those readings to an insulin pump.  In an advanced system, the pump would house a sophisticated computer program that would automatically calculate the necessary amount of insulin, based on the CGM's glucose readings, and deliver the right amount of insulin.  

The development of an artificial pancreas system is an essential step toward an ultimate cure for type 1 diabetes – a "bridge to a cure."

More information about the JDRF Artificial Pancreas Project is available at  http:///The site includes information for people with type 1 diabetes about research leading to the development of an artificial pancreas, as well as interactive tools, project timelines, chats with researchers, and access to information about clinical trials.

About JDRF

JDRF is a global leader in research leading to better treatments and cures for type 1 diabetes.  It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide.  

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.  For more information, please visit

SOURCE Juvenile Diabetes Research Foundation



SOURCE Juvenile Diabetes Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
2. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
3. The ZigBee Alliance and Continua Health Alliance Collaborate to Expand Telehealth Capabilities
4. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
5. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
8. febit and TGen Collaborate to Study New DNA Capture Method
9. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
Post Your Comments:
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):